VBI sells vaccine and facility for $33M; Bayer gets radioisotopes from PanTera; Thermo Fisher’s PPD expands offerings

15 Feb 2024

VaccinemRNAClinical Study

Welcome to Endpoints News ’ manufacturing briefs, where we bring you essential updates on new builds, collaborations, recalls and more. VBI Vaccines is selling its HBV HBV vaccine asset VBI-2601 and its facility in Rehovot, Israel, to Brii Biosciences for $33 million, it announced on Wednesday. The two companies previously extended their HBV partnership in July last year to develop VBI-2601. Brii will now also gain the rights to develop and commercialize VBI-2601 in Asia Pacific, apart from Japan. The deal is predicted to close at the end of June this year. Both companies will work to transfer manufacturing to a site chosen by Brii Bio.

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

Bayer AGThermo Fisher Israel Ltd.Brii Biosciences Limited

[+3]

Indications

Targets

Drugs

Hepatitis B vaccine recombinant(Sanofi)VBI-2601

Hot reports

Global Drug R&D Express (Apr 2024)

PatSnap Synapse

Global Drug R&D Express (Mar 2024)

PatSnap Synapse

Global Drug R&D Express (Feb 2024)

PatSnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.